Development of Prodrugs for Enzyme-Mediated, Tumor-Selective Therapy

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Development of Prodrugs for Enzyme-Mediated, Tumor-Selective Therapy

Anti-Cancer Agents in Medicinal Chemistry, 5(2): 107-113.

Author(s): K. Jin Yoon, Philip M. Potter and Mary K Danks.

Affiliation: Department of Molecular Pharmacology, St. Jude Children's Research Hospital.


Anticancer enzyme / prodrug approaches to therapy are designed to activate prodrugs specifically at tumor loci, to achieve antitumor responses with minimal toxicity. The equivocal success of these approaches thus far has led to searches for more efficient combinations. This mini-review evaluates and compares characteristics of seven selected enzyme / prodrug combinations, and discusses goals for future development of effective combinations.


enzyme prodrug therapy, hsv-tk gcv, Herves Simplex Virus-Thymidine Kinase Ganciclovir, cd 5-fc, cytosine deaminase 5-fluorocytosine, pnpase 2-f-araa, purine nucleoside phosphorylase 2-fluoroarabinosyl adenine.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 5
Issue Number: 2
First Page: 107
Last Page: 113
Page Count: 7
DOI: 10.2174/1568011053174837
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science